Topics
Glioblastoma | Treatment | Clinical trials | Bevacizumab and other angiogenesis inhibitors
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Bevacizumab
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto
Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama
Y, Miyake K, Sasaki H.
An exploratory
prospective phase II study of preoperative neoadjuvant bevacizumab
and temozolomide for newly diagnosed glioblastoma.
J
Neurooncol. 2024 Jan 31. doi:
10.1007/s11060-023-04544-8. PMID:
38291182. Interventional
study. ˍ
Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, Gao Y, Mei J, Yan Z,
Zhao R, Wang M, Li T, Bu X.
Predicting
recurrent glioblastoma clinical outcome to immune checkpoint
inhibition and low-dose bevacizumab with tumor in situ fluid
circulating tumor DNA analysis.
Cancer
Immunol Immunother. 2024 Aug 6;73(10):193. doi:
10.1007/s00262-024-03774-7. PMID:
39105794. Interventional study. ˍ
Motamed-Sanaye A, Mortezaei A, Afshari AR, Saadatian Z, Faraji AH,
Sheehan JP, Mokhtari AM.
Angiogenesis
inhibitors effects on overall survival and progression-free
survival in newly diagnosed primary glioblastoma multiforme: a
meta-analysis of twelve randomized clinical trials.
J
Neurooncol. 2024 Dec 5. doi:
10.1007/s11060-024-04865-2. PMID:
39636552. Meta-analysis˰
ˍ
Chen KT, Tsai HC, Huang CY, Liau CT, Ho KC, Toh CH, Chuang CC, Hsu
PW, Huang YC, Chang TW, Yeap MC, Chen PY, Lee CC, Lin YJ, Feng LY,
Airan RD, Li G, Lim M, Liu HL, Wei KC.
Combination
of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for
Patients With Recurrent Glioblastoma: A Pilot Study.
Neurosurgery.
2025 Nov 24. doi:
10.1227/neu.0000000000003851. PMID:
41283685. Interventional study. ˍ
Zhang J, Wang D, Liu G, Bu C, Lv G, Li M, Wei S, Zhang Z, Gao Y,
Yan Z, Ma C, Zhao R, Wang M, Shi Y, Bu X.
Dynamic
signature for the effectiveness of anti-PD-1 therapy combined with
vascular normalization therapy in recurrent glioblastoma: A
randomized phase 2 trial.
Cancer.
2026 Jan 15;132(2):e70253. doi:
10.1002/cncr.70253. PMID:
41533333.
Interventional study˰ ˍ
Lee J, Sim J, Lee YG, Lee GW, Jung HA, Kim KP, Kim TY, Ryu H, Ryu
MH, Ahn MS, Kwon M, Keam B, Bae JM, Kim S, Koo H, Kim SY, Kim JH,
Lee S.
Erlotinib
plus bevacizumab in EGFR-amplified metastatic solid tumors:
results from the KOSMOS I, II study of molecular profiling-guided
therapy in advanced cancers.
Int
J Clin Oncol. 2026 Jun 15. doi:
10.1007/s10147-026-03080-5. PMID:
42298055. Trial
registration ID: NCT05525858.
ˍ